Led · Series A · Jan 2023

ApnaKlub operates a digital B2B wholesale platform serving kirana stores and wholesalers in Tier-II and Tier-III cities. The startup will use new funding to enhance its platform and expand value-added offerings for customers. ApnaKlub has processed over two lakh orders and onboarded and transacted with more than 33,000 partners, signalling traction among small retailers and suppliers. The company was founded in 2020 by Shruti and Manish Kumar and is headquartered in Bengaluru. Management says the capital will allow continued platform growth and improved customer value. The firm also announced elevations within its product and growth leadership to founding-team status as part of its scaling plan. ApnaKlub operates a smartphone-enabled FMCG wholesale platform that lets individuals earn supplemental income by aggregating demand and supplying FMCG goods to local kirana stores. The company handles order aggregation, transport and inventory handling, offering a zero-capital model for partners. It plans to expand its partner base from 5,000 to 20,000 to reach underserved Indian communities and to deepen infrastructure in key states. ApnaKlub also intends to build out a credit product to support partners. The startup was incubated with Whiteboard Capital in 2020 by founders Shruti Shruti and Manish Kumar, who bring experience across product, strategy and FMCG distribution, including roles at Bain, Omidyar, Walmart India, Metro Cash & Carry and Future Group. The company is based in Bengaluru, India. ApnaKlub provides kirana and general stores with consistent supply and assortment of FMCG SKUs via a network of digitally connected wholesale partners who aggregate local demand and place orders on the app. The platform delivers goods to wholesale partners, who then distribute to retail stores, and has onboarded over 5,000 trained partners. ApnaKlub plans to expand its presence in rural India and to launch new services and products for its partners. It also intends to offer pricing and market intelligence data to small and large brands. The company was founded in 2020 by Shruti and Manish Kumar and is headquartered in Bengaluru. To date it has raised a total of $5 million. ApnaKlub is a social commerce startup that enables individuals with smartphones to earn income by aggregating demand and supplying fast moving consumer goods (FMCG) to local kirana stores. The platform provides unorganised ground-level wholesalers an organised supply infrastructure with competitive pricing and consistent product availability. It also offers a direct-to-partner-customer delivery service in which associate partners can deliver products directly to customers at predetermined prices. Since launching in 2020, ApnaKlub serviced over 2,500 partners across 4,500 pin codes within seven months of inception. The company targets semi-urban and rural (Tier 2/3) India and builds independent sales networks for brands seeking penetration into those markets. ApnaKlub plans to use the investment to deepen rural reach, expand its technology and operations teams, and broaden services and brand offerings for onboarded partners.

Led · Series B · Jul 2021

Axio Biosolutions develops proprietary biomaterial-based hemostatic and advanced wound care products, including Axiostat and MaxioCel. Axiostat is a chitosan-based first-aid dressing that stops bleeding within 2–3 minutes; MaxioCel is positioned to accelerate healing of chronic and acute wounds. The company’s products are available in India, Europe and more than 40 other countries, and it recently received US FDA clearance for Axiostat and an EU CE mark for MaxioCel. Axio operates from Boston and Bengaluru through Axio Biosolutions Private Limited in India. With this Series B2 equity round the company has raised over $20 million to date and plans to expand its commercial presence in the US and EU while strengthening operations in India. Leadership cites R&D, regulatory approvals and its patented biomaterial technology as central to broadening its portfolio of regulatorily approved surgical and wound-care products. Axio Biosolutions is described in the article as a medtech start-up. The company has raised Rs36 crores (about $5.2 million) in a Series B-1 round. The round was led by Omidyar Network India. Participation came from existing investors Accel, University of California & Ratan Tata’s UC-RNT Fund, and Chiratae Ventures. The article does not provide details on the company's products, future plans, or other operating metrics. Axio Biosolutions is an India-based medical devices firm. The company has raised $7.4 million in a Series B funding round. The Series B was led by Ratan Tata’s RNT Capital. The article does not disclose other participating investors, a valuation, use of proceeds, founding year, or operating metrics. No product details or future plans were provided beyond the company being described as a medical devices firm. The coverage appeared in DealStreetAsia’s reporting.